• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三例临床表现不同的低磷酸酯酶症患者的医疗资源利用情况。

Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations.

机构信息

Department of Paediatric Endocrinology & Metabolic Bone Diseases, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK.

Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK.

出版信息

Orphanet J Rare Dis. 2018 Aug 16;13(1):142. doi: 10.1186/s13023-018-0869-4.

DOI:10.1186/s13023-018-0869-4
PMID:30115096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6097329/
Abstract

BACKGROUND

Hypophosphatasia (HPP) is a rare, heterogeneous disease caused by low tissue-nonspecific alkaline phosphatase activity and associated with a range of signs and symptoms, including bone mineralization defects, respiratory problems, seizures, premature tooth loss, and fractures. Data from patients with HPP and their healthcare resource utilization are lacking. We evaluated healthcare utilization for 3 patients with differing severities of HPP.

RESULTS

Patient 1 had perinatal HPP (received enzyme replacement therapy asfotase alfa under a compassionate use program), Patient 2 had infantile HPP, and Patient 3 had childhood HPP. Healthcare resources used in the National Health Service, England, were identified from coded activities in the hospital database and detailed medical records. These data showed that healthcare utilization was directly related to disease severity. Patient 1 had respiratory complications necessitating prolonged admission for ventilation from birth. Over 2.5 years, this patient was hospitalized 725 days, with visits from 16 specialists. Patient 2 had HPP-associated signs and symptoms starting in infancy, was treated for craniosynostosis, experienced multiple fractures, and required outpatient management for > 18 years. Patient 3 developed signs and symptoms of HPP in childhood and received outpatient and day case treatment for dental, orthopedic, and cardiovascular problems over 24 years. Healthcare utilization varied with severity and complexity of disease manifestations between these patients.

CONCLUSIONS

With the recent approval of asfotase alfa for HPP, data from this analysis may help mobilize multidisciplinary healthcare resources for management of HPP by elucidating healthcare resource needs of patients who show a spectrum of clinical manifestations of HPP.

摘要

背景

低磷酸酯酶症(HPP)是一种罕见的、异质性疾病,由组织非特异性碱性磷酸酶活性降低引起,并伴有一系列的体征和症状,包括骨骼矿化缺陷、呼吸问题、癫痫发作、过早牙齿脱落和骨折。关于 HPP 患者及其医疗资源利用的数据尚缺乏。我们评估了 3 名具有不同严重程度 HPP 患者的医疗资源利用情况。

结果

患者 1 患有围产期 HPP(根据同情用药计划接受阿法特酶替代治疗),患者 2 患有婴儿期 HPP,患者 3 患有儿童期 HPP。在英国国家医疗服务体系中使用的医疗资源是从医院数据库和详细病历中的编码活动中确定的。这些数据表明,医疗资源的利用与疾病的严重程度直接相关。患者 1 因呼吸并发症需要从出生起就进行长时间的通气住院治疗。在 2.5 年多的时间里,该患者住院 725 天,接受了 16 名专家的治疗。患者 2 在婴儿期出现与 HPP 相关的体征和症状,接受了颅缝早闭治疗,经历了多次骨折,并需要进行超过 18 年的门诊管理。患者 3 在儿童期出现 HPP 的体征和症状,在 24 年的时间里接受了口腔、骨科和心血管问题的门诊和日间手术治疗。这 3 名患者的医疗资源利用情况因疾病表现的严重程度和复杂性而异。

结论

随着阿法特酶治疗 HPP 的近期获批,该分析的数据可能有助于通过阐明具有 HPP 多种临床表现的患者的医疗资源需求,为 HPP 的多学科医疗资源管理提供动力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a867/6097329/2192835acf7f/13023_2018_869_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a867/6097329/2192835acf7f/13023_2018_869_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a867/6097329/2192835acf7f/13023_2018_869_Fig1_HTML.jpg

相似文献

1
Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations.三例临床表现不同的低磷酸酯酶症患者的医疗资源利用情况。
Orphanet J Rare Dis. 2018 Aug 16;13(1):142. doi: 10.1186/s13023-018-0869-4.
2
Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.阿法特酶治疗低磷酸酯酶症患者的监测指导。
Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25.
3
Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.阿法磷酸酶:儿科发病低磷酸酯酶症的综述。
Drugs. 2016 Feb;76(2):255-62. doi: 10.1007/s40265-015-0535-2.
4
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.阿法骨化醇治疗可提高围产期和婴儿期低磷酸酯酶症的生存率。
J Clin Endocrinol Metab. 2016 Jan;101(1):334-42. doi: 10.1210/jc.2015-3462. Epub 2015 Nov 3.
5
Hypophosphatasia: From Diagnosis to Treatment.低磷酸酯酶症:从诊断到治疗。
Curr Rheumatol Rep. 2018 Sep 10;20(11):69. doi: 10.1007/s11926-018-0778-5.
6
Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.阿法骨化醇酶:用于治疗低磷性骨病的酶替代疗法。
Drugs Today (Barc). 2016 May;52(5):271-85. doi: 10.1358/dot.2016.52.5.2482878.
7
Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth.出生后第1天起采用酶替代疗法成功治疗致死性低磷酸酯酶症。
Eur J Pediatr. 2016 Mar;175(3):433-7. doi: 10.1007/s00431-015-2641-2. Epub 2015 Oct 12.
8
Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial.低磷酸酯酶症患者使用阿法骨化醇治疗的安全性和有效性:一项日本临床试验的结果。
Clin Endocrinol (Oxf). 2017 Jul;87(1):10-19. doi: 10.1111/cen.13343. Epub 2017 May 2.
9
Asfotase alfa therapy for children with hypophosphatasia.阿法磷酸酶治疗低磷酸酶血症儿童。
JCI Insight. 2016 Jun 16;1(9):e85971. doi: 10.1172/jci.insight.85971.
10
Enzyme Replacement Therapy in Hypophosphatasia.低磷酸酯酶症的酶替代疗法
J Coll Physicians Surg Pak. 2018 Sep;28(9):S198-S200. doi: 10.29271/jcpsp.2018.09.S198.

引用本文的文献

1
Pain, quality of life, and integral management in a cohort of patients diagnosed with hypophosphatasia in Colombia.在哥伦比亚被诊断为低磷酸酯酶症的患者队列中,疼痛、生活质量和整体管理。
Orphanet J Rare Dis. 2024 Nov 6;19(1):417. doi: 10.1186/s13023-024-03366-9.
2
The Clinical Picture of Patients Suffering from Hypophosphatasia-A Rare Metabolic Disease of Many Faces.低磷酸酯酶症患者的临床症状——一种具有多种表现的罕见代谢性疾病
Diagnostics (Basel). 2022 Mar 30;12(4):865. doi: 10.3390/diagnostics12040865.
3
A Japanese single-center experience of the efficacy and safety of asfotase alfa in pediatric-onset hypophosphatasia.

本文引用的文献

1
Clinical, radiographic and biochemical characteristics of adult hypophosphatasia.成人生性低磷酸酯酶症的临床、影像学和生化特征。
Osteoporos Int. 2017 Sep;28(9):2653-2662. doi: 10.1007/s00198-017-4087-z. Epub 2017 May 25.
2
Hypophosphatasia: An overview For 2017.低磷酸酯酶症:2017 年概述。
Bone. 2017 Sep;102:15-25. doi: 10.1016/j.bone.2017.02.011. Epub 2017 Feb 24.
3
Asfotase alfa therapy for children with hypophosphatasia.阿法磷酸酶治疗低磷酸酶血症儿童。
阿法磷酸酶治疗儿童发病型低磷酸酯酶症的日本单中心疗效和安全性研究
Orphanet J Rare Dis. 2022 Feb 23;17(1):78. doi: 10.1186/s13023-022-02230-y.
4
Hypophosphatasia.低磷酸酯酶症
J Clin Med. 2021 Dec 1;10(23):5676. doi: 10.3390/jcm10235676.
5
Clinical and genetic aspects of mild hypophosphatasia in Japanese patients.日本患者轻度低磷酸酯酶症的临床与遗传学特征
Mol Genet Metab Rep. 2019 Oct 11;21:100515. doi: 10.1016/j.ymgmr.2019.100515. eCollection 2019 Dec.
JCI Insight. 2016 Jun 16;1(9):e85971. doi: 10.1172/jci.insight.85971.
4
Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys.成人低磷酸酯酶症患者的疾病负担:两项患者报告调查的结果。
Metabolism. 2016 Oct;65(10):1522-30. doi: 10.1016/j.metabol.2016.07.006. Epub 2016 Jul 19.
5
Hypophosphatasia.低磷酸酯酶症
Curr Osteoporos Rep. 2016 Jun;14(3):95-105. doi: 10.1007/s11914-016-0309-0.
6
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe.欧洲杜氏肌营养不良症患者的社会/经济成本及与健康相关的生活质量
Eur J Health Econ. 2016 Apr;17 Suppl 1:19-29. doi: 10.1007/s10198-016-0782-5. Epub 2016 Apr 2.
7
Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.低磷酸酯酶症——病因学、命名法、发病机制、诊断和治疗。
Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19.
8
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.英国非住院囊性纤维化患者的社会经济成本及健康相关生活质量
BMC Health Serv Res. 2015 Sep 28;15:428. doi: 10.1186/s12913-015-1061-3.
9
Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients.低磷性骨软化症:基于25年173例儿科患者经验对儿童临床疾病分类学的验证与扩展
Bone. 2015 Jun;75:229-39. doi: 10.1016/j.bone.2015.02.022. Epub 2015 Feb 27.
10
Hypophosphatasia.低磷酸酯酶症
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8.